投资者关系活动记录表 证券代码：300290 证券简称：荣科科技 编号：2015-001 | --- | --- | --- | |----------|------------------------|------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系活动类 | □ 新闻发布会 □路演活动 | | | 别 | □ 现场参观 | | | | √ 其他 （战略发布会） | | | 参与单位 | | 方正富邦基金 高松、东北证券 吴雁 许祥、海通资管 童胜、民生证券 | | 名称及人 | | 马松、中金基金 郭党钰、东岭投资 王顺欢、中金公司 张景松、齐鲁资 | | 员姓名 | | 管 应晓晨、达仁资管 杨尚烨、国联安基金 郑青、中银基金 刘潇、敦和 | | | | 资管 安昀 黄国珍、长江养老保险 邓锐、国金自营 袁艺博、国泰基金 | | | | 刘健维、东吴基金 朱冰兵、从容投资 沈磊、本翼资本 金麟凤 ...

投资者关系活动记录表 证券代码：300290 证券简称：荣科科技 荣科科技股份有限公司投资者关系活动记录表 编号：2016-002 | --- | --- | --- | |-----------------------|------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 铭基国际投资公司 祝泉 | | | 人员姓名 | | | | 时间 | 2016 年 2 月 4 | 日 14： 00 | | 地点 上市公司接待人 | 公司会议室 | | | 员姓名 | | 财务总监兼董事会秘书冯丽女士、投资总监张羽先生 | | 投资者关系活动 | | 一、介绍公司智慧医疗发展战略及规划 | | | 二、交流环节 | | ...

投资者关系活动记录表 证券代码：300290 证券简称：荣科科技 荣科科技股份有限公司投资者关系活动记录表 编号：2016-003 | --- | --- | --- | |----------------|------------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 海通证券股份有限公司 王鸣阳 | | | 人员姓名 | | | | 时间 | 2016 年 11 月 21 | 日 15： 00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | | 财务总监兼董事会秘书冯丽女士、投资总监张羽先生 | | 投资者关系活动 | 一、介绍公司智慧医疗发展战略及规划 | ...

投资者关系活动记录表 证券代码：300290 证券简称：荣科科技 荣科科技股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | |----------------|-----------------------------|------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | | | 人员姓名 | 信达证券股份有限公司 袁海宇 | | | 时间 | 2018 年 1 月 30 | 日 14：30 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | | 董事会秘书张羽、证券事务代表徐蓉蓉 | 1 投资者关系活动记录表 | --- | --- | |----------------|--------------------------- ...

投资者关系活动记录表 证券代码：300290 证券简称：荣科科技 荣科科技股份有限公司投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |----------------|-----------------------------|------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | | | 人员姓名 | 东北证券股份有限公司 何柄谕 | | | 时间 | 2018 年 1 月 29 | 日 15：00 | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | 员姓名 | | 董事会秘书张羽、证券事务代表徐蓉蓉 | 1 投资者关系活动记录表 | --- | --- | |----------------|--------------------------- ...

Acquisitions and Business Expansion - The company has completed acquisitions of Shanghai Mijian, Beijing Shenzhou Shihan, and Shanghai Jinchuang, enhancing its position in the medical information technology sector[4] - The company plans to deepen its business lines and expand product offerings to smooth out seasonal revenue fluctuations, which are primarily concentrated in the fourth quarter[6] - The company continues to focus on the smart healthcare and health data sectors, leveraging a dual-wheel drive model of "subsidiary + platform" for market expansion[39] - The company is investing heavily in technology innovation and exploring new service models to improve user engagement and brand value[4] - The company is transitioning to a cloud value-added service provider, offering comprehensive solutions that include online and offline support for various industries[45] Financial Performance - The company's operating revenue for the reporting period was ¥302,731,206.63, a decrease of 21.80% compared to the same period last year[32] - Net profit attributable to shareholders was ¥20,952,618.38, representing a significant increase of 72.34% year-on-year[32] - The net profit after deducting non-recurring gains and losses was -¥30,959,402.04, a decline of 428.51% compared to the previous year[32] - The net cash flow from operating activities improved by 25.23%, amounting to -¥121,594,663.18[32] - The total assets at the end of the reporting period were ¥1,717,124,147.86, down 8.40% from the end of the previous year[32] Risks and Challenges - The company has identified risks related to goodwill impairment from acquisitions, emphasizing the need for strong management of subsidiaries to mitigate this risk[10] - The company faces risks from intensified market competition and must innovate to maintain its competitive edge[4] - The company is committed to improving its talent retention strategies to combat the risk of losing high-quality personnel in a competitive market[7] Strategic Partnerships and Market Position - The company aims to strengthen strategic partnerships with domestic platform vendors to enhance market competitiveness amid global economic challenges[14] - The company plans to deepen cooperation with large industrial groups and strengthen R&D investment to maintain its competitive edge in the Northeast region[47] - The company aims to establish communication channels with national ministries and actively participate in national-level research associations to enhance its brand image[47] Innovation and Product Development - The smart hospital solution integrates products from subsidiaries, emphasizing a data-driven approach and utilizing big data, AI, and blockchain technologies[40] - The digital health city initiative aims to enhance healthcare services through a digital upgrade, focusing on user needs and establishing a digital health brain[43] - The company has added 39 new software copyrights during the reporting period, reflecting its commitment to innovation and product development[50] - The company is focused on enhancing the functionality and architecture of its cloud platform, exploring new industry solutions based on IoT and data middle platforms[45] Financial Management and Investments - The company reported a fair value change loss of ¥88,006,343.75 during the reporting period, with total fair value assets amounting to ¥123,887,972.92[69] - The company has no financial liabilities reported, indicating a strong balance sheet position[64] - The total investment amount for the reporting period was ¥2,029,814.92, a significant decrease of 97.57% compared to ¥83,616,622.94 in the same period last year[66] - The company has committed to returning bank loans totaling 1,217.50 million, fully realized[77] Shareholder and Governance Matters - The company will not distribute cash dividends or issue bonus shares for the reporting period[15] - The company held a temporary shareholders' meeting on April 1, 2022, with an investor participation rate of 21.51%[85] - The company held its annual shareholders' meeting on June 2, 2022, with an investor participation rate of 20.23%[85] - The company has committed to not engaging in any related party transactions that could harm its interests or those of its shareholders[100] Social Responsibility and Community Engagement - The company has been recognized as a key enterprise for epidemic prevention and control by the Liaoning Provincial Department of Industry and Information Technology, reflecting its significant role in public health during the pandemic[94] - The company has strengthened its commitment to social responsibility, particularly in the fields of smart cities and healthcare, addressing community needs and enhancing public welfare[89] - The company has created job opportunities and enhanced employee engagement during the pandemic, providing training and support to employees facing operational challenges[95] Compliance and Regulatory Matters - The company has committed to compensating for any losses incurred due to violations of its commitments[100] - The company has implemented a stock incentive plan with a lock-up period of 12, 24, and 36 months for the granted restricted stocks[105] - The company has taken measures to ensure compliance with internal controls regarding guarantee responsibilities[106] Financial Reporting and Accounting Practices - The financial statements are prepared based on the enterprise accounting standards, ensuring a true and complete reflection of the company's financial status[175] - The company has established policies for handling transaction costs related to mergers, recognizing them as expenses in the period incurred[180] - The company recognizes expected credit losses based on the risk of default weighted by the average expected loss over the life of the financial instrument[199]

Financial Performance - The company's revenue for Q1 2022 was ¥117,915,538.19, a decrease of 16.95% compared to ¥141,983,062.98 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥23,275,506.84, representing a decline of 1,074.94% from a profit of ¥2,387,374.05 in Q1 2021[3] - Basic and diluted earnings per share were both -¥0.0365, a decrease of 1,012.50% from ¥0.0040 in Q1 2021[3] - Net profit for Q1 2022 was a loss of ¥20,730,010.84, compared to a profit of ¥4,403,859.62 in Q1 2021, indicating a significant decline in profitability[23] - Total operating revenue for Q1 2022 was ¥117,915,538.19, a decrease of 16.9% compared to ¥141,983,062.98 in Q1 2021[21] - Total operating costs for Q1 2022 were ¥138,720,594.82, down 5.5% from ¥146,744,917.97 in the previous year[21] Cash Flow - The net cash flow from operating activities was negative at ¥158,765,752.43, which is a 5.78% increase in cash outflow compared to ¥150,097,216.16 in the previous year[3] - Cash flow from operating activities was ¥132,148,083.00 in Q1 2022, down from ¥147,783,146.83 in Q1 2021, reflecting a decrease of 10.6%[24] - Total cash inflow from operating activities was $140,136,790.44, while total cash outflow was $298,902,542.87, resulting in a significant cash outflow[25] - The net cash flow from investing activities was -$11,068,448.56, a decrease from -$46,025,424.92 year-over-year, showing an improvement of approximately 76.0%[26] - Cash inflow from financing activities totaled $7,192,264.18, while cash outflow was $45,456,386.37, leading to a net cash flow from financing activities of -$38,264,122.19[26] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,740,536,945.88, down 7.15% from ¥1,874,629,684.36 at the end of the previous year[3] - Total liabilities decreased to ¥677,447,274.54 in Q1 2022 from ¥790,960,002.18 in Q1 2021, a reduction of 14.3%[20] - The company’s total equity decreased to ¥1,063,089,671.34 in Q1 2022 from ¥1,083,669,682.18 in Q1 2021, a decline of 1.9%[20] - Total current assets decreased from 1,233,191,095.06 CNY to 1,096,044,783.21 CNY, a reduction of about 11.1%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period was 23,672[12] - The largest shareholder, Henan Xinchuan Shuchuang Private Equity Investment Fund, holds 20.02% of shares, totaling 128,000,000 shares[12] Expenses - Sales expenses increased by 33.10% to ¥22,055,075.77 compared to ¥16,569,728.24 in Q1 2021, primarily due to increased sales efforts and personnel investment[9] - Research and development expenses increased to ¥14,775,317.77 in Q1 2022, up from ¥12,658,512.52 in Q1 2021, indicating a focus on innovation[21] Investment Performance - Investment income showed a significant loss of ¥945,862.11, a decline of 1,511.91% compared to a profit of ¥66,991.60 in the previous year[9] - Cash inflow from investment activities decreased by 97.73% to ¥794,832.20 from ¥35,071,047.55 in Q1 2021[10] Management Changes - The company announced the resignation of its chairman and another board member due to work changes and personal reasons[15] - The board of directors proposed new candidates for non-independent directors, which were approved at the shareholders' meeting[15] Other Information - The company did not conduct an audit for the first quarter report[27] - The report was released by the board of directors on April 28, 2022[28]

Financial Performance - The company reported a significant loss for the year, with specific reasons and measures for improving profitability detailed in the management discussion section[6]. - The company's operating revenue for 2021 was RMB 817,309,721.17, representing a 3.73% increase compared to RMB 787,896,467.61 in 2020[25]. - The net profit attributable to shareholders for 2021 was a loss of RMB 404,820,551.48, a decrease of 603.71% from a profit of RMB 80,368,462.37 in 2020[25]. - The net cash flow from operating activities for 2021 was RMB 455,136.20, down 99.60% from RMB 113,833,220.60 in 2020[25]. - The total assets at the end of 2021 were RMB 1,874,629,684.36, a decrease of 5.46% from RMB 1,982,963,071.10 at the end of 2020[25]. - The net assets attributable to shareholders at the end of 2021 were RMB 1,037,189,051.24, down 24.06% from RMB 1,365,823,220.26 at the end of 2020[25]. - The basic earnings per share for 2021 was -RMB 0.6538, a decline of 566.00% from RMB 0.1403 in 2020[25]. - The diluted earnings per share for 2021 was also -RMB 0.6538, a decrease of 568.67% from RMB 0.1395 in 2020[25]. - The weighted average return on equity for 2021 was -33.44%, a drop of 40.02 percentage points from 6.58% in 2020[25]. - The company reported a significant decline in net profit, with a loss of RMB 368,944,269.35 after deducting non-recurring gains and losses in the fourth quarter[28]. Acquisitions and Business Strategy - The company completed acquisitions of 100% of MiJian Information and ShenZhou Vision, and 80% of Shanghai JinChuang, enhancing its position in the medical information technology sector[9]. - The company plans to integrate its business systems, organizational structure, and marketing networks post-acquisition to enhance profitability and core competitiveness[10]. - The company is pursuing a strategy of domestic substitution in technology, planning to strengthen its market position over the next three years[43]. - The company aims to leverage national policies and economic advantages to enhance its core business areas of smart healthcare and smart cities, targeting a leadership role in these sectors[111]. Market and Industry Trends - The aging population in China is projected to exceed 210 million by 2025, increasing the demand for healthcare services significantly[34]. - The COVID-19 pandemic has accelerated the demand for digital healthcare services, highlighting the need for online medical consultations[35]. - The company anticipates growth opportunities in the smart healthcare and cloud industry due to favorable government policies and economic stability[37]. - The smart healthcare market in China is projected to grow rapidly, with the industry size surpassing 100 billion yuan in recent years, driven by government support and digital economy advancements[111]. Risks and Challenges - The company faces risks related to market competition, emphasizing the need for technological and business model innovation to maintain competitiveness[7]. - The company acknowledges potential risks from global economic slowdowns and geopolitical tensions that could impact its operations and market conditions[10]. - The company is experiencing seasonal revenue fluctuations, with significant income typically realized in the fourth quarter due to client budgeting and procurement cycles[7]. Research and Development - The company reported a research and development investment of ¥99,128,147.31 in 2021, representing 12.13% of its operating revenue, an increase from 9.62% in 2020[78]. - The company is committed to advancing its technology through continuous research and development in healthcare and energy sectors[46]. - The company registered 95 new software copyrights during the reporting period, enhancing its intellectual property portfolio[45]. - The company has developed a comprehensive health data management system, which is expected to improve healthcare service delivery[45]. Governance and Management - The company appointed He Renhui as the new CEO and promoted Ling Xingang to Vice President following the board restructuring[130]. - The board of directors underwent a significant change with the resignation of four directors and the appointment of new members, including He Hangxiao and Hu Changgen[129]. - The company has implemented strict internal control systems to ensure independence from its controlling shareholder in various aspects[123]. - The company is focused on enhancing its governance framework to support its strategic objectives and market expansion[129]. Financial Obligations and Compliance - The company reported a significant increase in development expenditures to ¥18,527,080.94, which is 0.99% of total assets, attributed to increased R&D investments[89]. - The company is actively managing its financial obligations and ensuring compliance with regulatory requirements regarding guarantees and liabilities[192]. - The company reported a total of ¥25,582.97 million in guarantees, with ongoing communication regarding the resolution of these issues[192]. - The company has committed to ensuring that all transactions with related parties are conducted fairly and transparently, adhering to legal and regulatory requirements[184]. Employee and Talent Management - The company has established a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders and management[121]. - The total employee compensation for the year was CNY 207.47 million, with core technical personnel compensation totaling CNY 40.66 million, accounting for 19.60% of the total[158]. - The number of R&D personnel decreased by 13.60% from 353 in 2020 to 305 in 2021, with R&D personnel now accounting for 29.24% of the total workforce[77]. Future Outlook - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, which reflects an expected growth of 20%[144]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative technology solutions[143]. - The company plans to increase its marketing budget by 30% to boost brand awareness and customer engagement[144].

1 关于参加 2021 年辽宁辖区上市公司投资者网上集体接待日活动的公告 证券代码：300290 证券简称：荣科科技 公告编号：2021-116 荣科科技股份有限公司 关于参加2021年辽宁辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，荣科科技股份有限公司（以下简称"公司"） 将参加"2021 年辽宁辖区上市公司投资者网上集体接待日"活动。 投资者可于 2021 年 12 月 10 日（周五）15:30 至 17:00，登陆全景网投资者关 系互动平台（https://ir.p5w.net/）参与本次活动。届时公司高管将通过网络在线 交流的形式，与投资者就公司治理、经营状况、发展战略、风险防控、投资者保护 等投资者关注的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 荣科科技股份有限公司董事会 二〇二一年十二月七日 ...

荣科科技股份有限公司 2021 年第三季度报告 证券代码：300290 证券简称：荣科科技 公告编号：2021-103 荣科科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计：□ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 增减 | | 上年同期增减 | | 营业收入（元） | 288,274,336.33 | 44.48% | 675,407,500.85 | 40.53% | | ...